Related Experiment Video
Updated: Jan 5, 2026

06:59
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
11.4K
[Rat metabolic parameters in multiple insulin hy- 44poglycemia]
Summary
Repeated insulin-induced hypoglycemic coma in rats elevates serum free fatty acids, urea, and uric acid. Liver enzyme activity increases, indicating enhanced amino acid catabolism and gluconeogenesis.
Area of Science:
- Biochemistry
- Physiology
- Endocrinology
Context:
- Insulin-induced hypoglycemia is a critical complication of diabetes treatment.
- Understanding the metabolic adaptations to recurrent hypoglycemia is crucial for managing patients.
- Previous studies have focused on acute effects, but chronic adaptations remain less understood.
Purpose:
- To investigate the metabolic and enzymatic changes in the liver following repeated episodes of insulin-induced hypoglycemic coma.
- To determine if chronic hypoglycemia leads to distinct physiological adaptations compared to acute exposure.
- To elucidate the role of hepatic enzyme activity in the response to recurrent hypoglycemia.
Summary:
- Rats subjected to multiple hypoglycemic comas showed elevated serum free fatty acids, urea, and uric acid, while hepatic glycogen remained normal.
- Liver enzyme activities, including aspartate aminotransferase, alanine aminotransferase, glutaminase, glutamate dehydrogenase, succinate dehydrogenase, and lactate dehydrogenase, were significantly enhanced.
- Increased lactate generation from glucose and glycogen substrates was observed, suggesting heightened metabolic activity.
- These adaptive changes, including increased amino acid catabolism and gluconeogenesis, were absent in animals experiencing only a single hypoglycemic coma.
Impact:
- This study reveals significant metabolic reprogramming in the liver in response to recurrent hypoglycemia.
- The findings suggest a stimulated counter-regulatory hormonal response to manage repeated low blood glucose states.
- Provides insights into the biochemical mechanisms underlying adaptation to chronic hypoglycemia, relevant for clinical management strategies.
Related Concept Videos
Hypoglycemia and Glucagon
757
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
757
Insulin: Dosing Regimen and Adverse Effects
631
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
631
Oral Hypoglycemic Agents: Biguanides and Glitazones
550
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
550
Glucose Homeostasis: Regulation of Blood Glucose
3.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K
Oral Hypoglycemic Agents: Glinides
549
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
549
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K

